These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 27797623)
1. Making the most of every option in the treatment of ovarian cancer. du Bois A Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):1. PubMed ID: 27797623 [No Abstract] [Full Text] [Related]
2. Platinum or nonplatinum in recurrent ovarian cancer: that is the question. Poveda A; Marth C Future Oncol; 2017 Oct; 13(23s):11-16. PubMed ID: 29020823 [TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer. Fujiwara K Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():354-8. PubMed ID: 10895180 [No Abstract] [Full Text] [Related]
10. Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin. González-Martín A; du Bois A Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):3-10. PubMed ID: 27797624 [TBL] [Abstract][Full Text] [Related]
11. E2F1 as a molecular drug target in ovarian cancer. Farra R; Dapas B; Grassi M; Benedetti F; Grassi G Expert Opin Ther Targets; 2019 Mar; 23(3):161-164. PubMed ID: 30724632 [No Abstract] [Full Text] [Related]
12. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699 [TBL] [Abstract][Full Text] [Related]
13. Increasing the chances for platinum-sensitive ovarian cancer patients. González A Future Oncol; 2013 Dec; 9(12 Suppl):29-35. PubMed ID: 24195528 [TBL] [Abstract][Full Text] [Related]
14. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. Marchetti C; Palaia I; De Felice F; Musella A; Donfracesco C; Vertechy L; Romito A; Piacenti I; Musio D; Muzii L; Tombolini V; Benedetti Panici P Cancer Treat Rev; 2016 Jan; 42():41-6. PubMed ID: 26559739 [TBL] [Abstract][Full Text] [Related]
15. [Impact of molecular classification on clinical management of ovarian cancer]. Hasegawa K Gan To Kagaku Ryoho; 2015 Feb; 42(2):166-8. PubMed ID: 25834913 [No Abstract] [Full Text] [Related]
16. Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. Colombo N Future Oncol; 2013 Dec; 9(12 Suppl):19-23. PubMed ID: 24195526 [TBL] [Abstract][Full Text] [Related]
17. Current treatment and clinical trials in ovarian cancer. Han LY; Kipps E; Kaye SB Expert Opin Investig Drugs; 2010 Apr; 19(4):521-34. PubMed ID: 20367193 [TBL] [Abstract][Full Text] [Related]
19. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer. Teo MC Curr Opin Obstet Gynecol; 2014 Feb; 26(1):3-8. PubMed ID: 24247932 [TBL] [Abstract][Full Text] [Related]
20. Veliparib for the treatment of ovarian cancer. Bogliolo S; Cassani C; Dominoni M; Musacchi V; Venturini PL; Spinillo A; Ferrero S; Gardella B Expert Opin Investig Drugs; 2016; 25(3):367-74. PubMed ID: 26807493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]